Showing 6471-6480 of 10731 results for "".
DermwireTV — Sun Rises, ICD-10 is Delayed…Again
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-mdash-sun-rises-icd-10-is-delayed-again/19139/In this week's DermwireTV, Sun acquires Ranbaxy, ICD-10 gets unexpectedly delayed, and Murad Alam recaps the ASLMS conference.Oral Supplements for Dispensing
https://practicaldermatology.com/topics/practice-management/graf-2/19217/Oral supplements can support skin health and may be dispensed in the aesthetic practice.Coordinating the Skincare Team
https://practicaldermatology.com/topics/practice-management/coordinating-the-skincare-team/19218/Speaking at Vegas Cosmetic Surgery, Vivian Bucay, MD discussed was to optimize skincare dispensing in the aesthetic practice.Skin Resurfacing, Pixel RF from Alma Lasers
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/-skin-resurfacing-pixel-rf-from-alma-lasers/19241/Skin resurfacing with the innovative Pixel RF from Alma Lasers. Ready to fight the hands of time? Click here for more info: http://www.AlmaLasers.comThe Big Idea: Jeanine Downie, MD on Purchasing Her Own Space
https://practicaldermatology.com/topics/practice-management/the-big-idea-jeanine-downie-md-on-purchasing-her-own-space/19278/Dr. Downie explains why she wanted her own space and describes the major and minor benefits of ownership, including cost savings. Featured in "What's The Big Idea"Sunscreen Labeling
https://practicaldermatology.com/topics/practice-management/sunscreen-labeling-/19370/Neal Bhatia, MD discusses the impact of new sunscreen labeling on patient education, as well as strategies for UV avoidance, and trends in therapeutic development.Psoriasis Pipeline Update: JNJ-2113, A Novel Oral IL-23 Receptor Antagonist Peptide, Shows Promise in a Phase 2b Study
https://practicaldermatology.com/topics/psoriasis/psoriasis-pipeline-update-jnj-2113-a-novel-oral-il-23-receptor-antagonist-peptide-shows-promise-in-a-phase-2b-study/20207/Laura Korb Ferris, MD, PhD, discusses the topline results from a Phase 2b trial of JNJ-2113, a novel oral IL-23 receptor antagonist peptide that’s being developed for moderate-to-severe plaque psoriasis.“No-touch” Surgical Excision & “Double-freeze-thaw” Cryotherapy Techniques
https://practicaldermatology.com/topics/skin-cancer-photoprotection/conjunctival-scc/19861/A 68-year-old white male with a history of basal cell carcinoma of the right lower eyelid, surgically excised 10 years prior to presentation, was referred to the Ocular Oncology Service at Wills Eye Hospital, Philadelphia for an asymptomatic conjunctival lesion on the right eye. The patient was treaMaking Connections: Success in Your First Five Years
https://practicaldermatology.com/topics/practice-management/webinar-making-connections-success-in-your-first-five-years/19819/Experts share practical guidance to help dermatologists chart a course for success. Topics range from getting involved in clinical trials to finding opportunities for leadership. Learn how to gain confidence prescribing systemic agents, and explore opportunities in medical dermatology.DermWireTV: Climate Change and Skin, Wynzora, Tremfya, Rinvoq Updates
https://practicaldermatology.com/topics/psoriasis/dermwiretv-climate-change-and-skin-wynzora-tremfya-rinvoq-updates/19834/The vast majority of dermatologists around the world—95.6 percent—believe climate change is occurring, and 88 percent think it will impact the incidence of skin diseases, according to the first international survey of dermatologists on the topic, conducted online by the International Society of Derm